Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with target-ed drugs: pooled analysis of clinical trials from the German CLL Study Group (GCLLSG)

被引：0
|
作者：
Boccellato, Elia
Giza, Adam
Robrecht, Sandra
Cramer, Paula
von Tresckow, Julia
Al-Sawaf, Othman
Furstenau, Moritz
Tausch, Eugen
Stilgenbauer, Stephan
Fischer, Kirsten
Eichhorst, Barbara
Vitale, Candida
Coscia, Marta
Hallek, Michael
Langerbeins, Petra
机构：
来源：
LEUKEMIA & LYMPHOMA | 2023年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1548000
引用
收藏
页码：S4 / S5
页数：2
相关论文
共 50 条
  • [41] Occurrence and evolution of autoimmune cytopenias in chronic lymphocytic leukemia patients treated with venetoclax: a study of the French Innovative Leukemia Organization (FILO)
    Collignon, Aude
    Nudel, Morgane
    Brion, Annie
    Laribi, Kamel
    Nivet, Thomas
    Merabet, Fatiha
    Ysabaert, Loic
    Tournilhac, Olivier
    Le Guenno, Guillaume
    Tomowiak, Cecile
    Tchernonog, Emmanuelle
    Dupuis, Jehan
    Ghnaya, Habib
    Stocker, Nicolas
    Fayault, Alexandra
    Bene, Marie-C
    Aurran, Therese
    LEUKEMIA & LYMPHOMA, 2023, 64 : S159 - S160
  • [42] Second Primary Malignancies (SPM) in Chronic Lymphocytic Leukemia (CLL) after First-line Treatment: Results of a Metaanalysis of the German CLL Study Group (GCLLSG)
    Maurer, C.
    Langerbeins, P.
    Cramer, P.
    Bahlo, J.
    Fink, A. M.
    Fischer, K.
    Wendtner, C-M
    Hallek, M.
    Eichhorst, B.
    ONKOLOGIE, 2013, 36 : 221 - 221
  • [43] Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission - Experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL study group (GCLLSG).
    Wendtner, CM
    Ritgen, M
    Schweighofer, CD
    Fingerle-Rowson, G
    Campe, H
    Jaeger, G
    Eichhorst, B
    Busch, R
    Diem, H
    Engert, A
    Stilgenbauer, S
    Doehner, H
    Kneba, M
    Emmerich, B
    Hallek, M
    BLOOD, 2003, 102 (11) : 676A - 676A
  • [44] Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG)
    C-M Wendtner
    M Ritgen
    C D Schweighofer
    G Fingerle-Rowson
    H Campe
    G Jäger
    B Eichhorst
    R Busch
    H Diem
    A Engert
    S Stilgenbauer
    H Döhner
    M Kneba
    B Emmerich
    M Hallek
    Leukemia, 2004, 18 : 1093 - 1101
  • [45] Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission -: experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG)
    Wendtner, CM
    Ritgen, M
    Schweighofer, CD
    Fingerle-Rowson, G
    Campe, H
    Jäger, G
    Eichhorst, B
    Busch, R
    Diem, H
    Engert, A
    Stilgenbauer, S
    Döhner, H
    Kneba, M
    Emmerich, B
    Hallek, M
    LEUKEMIA, 2004, 18 (06) : 1093 - 1101
  • [46] Bendamustine, followed by obinutuzumab, acalabrutinib and venetoclax in patients (Pts) with relapsed/refractory chronic lymphocytic Leukemia (CLL): updated results of the CLL2-BAAG trial of the German CLL Study Group (GCLLSG)
    Cramer, Paula
    Fuerstenau, Moritz
    Robrecht, Sandra
    Giza, Adam
    Fink, Anna
    Fischer, Kirsten
    Langerbeins, Petra
    Al-Sawaf, Othman
    Tausch, Eugen
    Schneider, Christof
    Schetelig, Johannes
    Dreger, Peter
    Boettcher, Sebastian
    Kreuzer, Karl-Anton
    Schilhabel, Anke
    Brueggemann, Monika
    Kneba, Michael
    Wendtner, Clemens
    Stilgenbauer, Stephan
    Eichhorst, Barbara
    Hallek, Michael
    LEUKEMIA & LYMPHOMA, 2023, 64 : S18 - S19
  • [47] Outcomes and Treatment Sequences of Therapies with BCL2-and BTK Inhibitors in Chronic Lymphocytic Leukemia (CLL): An Analysis of Patient Data within the German CLL Study Group (GCLLSG) Registry
    Kutsch, Nadine
    Ligtvoet, Rudy
    Robrecht, Sandra
    Linde, Hartmut
    Illmer, Thomas
    Doerfel, Steffen
    Lipke, Joerg
    Aldaoud, Ali
    Schlag, Rudolf
    Dengler, Jolanta
    Al-Sawaf, Othman
    Langerbeins, Petra
    Cramer, Paula
    Eichhorst, Barbara F.
    Hallek, Michael
    Fischer, Kirsten
    Fink, Anna Maria
    BLOOD, 2023, 142
  • [48] First line therapy of patients (pts) with advanced chronic lymphocytic leukemia (CLL) older than 65 years with fludarabine versus chlorambucil: Interim analysis of a phase III study of the German CLL Study Group (GCLLSG).
    Schmitt, BF
    Kneba, M
    Ritgen, M
    Stauch, M
    Emmerich, B
    Bergmann, M
    Busch, R
    Wendtner, CM
    Hallek, M
    BLOOD, 2002, 100 (11) : 387A - 387A
  • [49] IGHV-Mutation Status, IGHV-Gene Usage and Chromosomal Aberrations In CLL: Pooled Analysis within First-Line Clinical Trials of the German CLL Study Group (GCLLSG)
    Buhler, Andreas
    Zenz, Thorsten
    Winkler, Dirk
    Busch, Raymonde
    Fischer, Kirsten
    Fink, Anna
    Wendtner, Clemens
    Eichhorst, Barbara
    Edelmann, Jennifer
    Hallek, Michael
    Doehner, Hartmut
    Stilgenbauer, Stephan
    BLOOD, 2010, 116 (21) : 1486 - 1486
  • [50] Value of Minimal Residual Disease (MRD) Negative Status at Response Evaluation in Chronic Lymphocytic Leukemia (CLL): Combined Analysis of Two Phase III Studies of the German CLL Study Group (GCLLSG)
    Kovacs, Gabor
    Boettcher, Sebastian
    Bahlo, Jasmin
    Kluth, Sandra
    Ritgen, Matthias
    Fink, Anna Maria
    Stodden, Irene
    Cramer, Paula
    von Tresckow, Julia
    Maurer, Christian
    Doehner, Hartmut
    Stilgenbauer, Stephan
    Kneba, Michael
    Fischer, Kirsten
    Hallek, Michael
    Eichhorst, Barbara
    BLOOD, 2014, 124 (21)
12345